OncoSec Medical Incorporated (NASDAQ:ONCS) is at least 34.92% than its current record low price of $0.54. There was a 5.11% gain on 01/11/2019 that led the price to move at $0.73. At recent session, the prices were hovering between $0.69 and $0.75. This company shares are 447.95% off its target price of $4 and the current market capitalization stands at $44.79M. The recent change has given its price a -18.19% deficit over SMA 50 and -66.97% deficit over its 52-week high. The stock witnessed -11.1% declines, -51.98% declines and -43.85% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ONCS’s volatility during a week at 8.68% and during a month it has been found around 9.54%.OncoSec Medical Incorporated (ONCS) Top Holders
Institutional investors currently hold around $5 million or 11.5% in ONCS stock. Look at its top three institutional owners. Vanguard Group Inc owns $1.43 million in OncoSec Medical Incorporated, which represents roughly 3.19% of the company’s market cap and approximately 28.6% of the institutional ownership. Similar statistics are true for the second largest owner, Point72 Asset Management, L.P., which owns 1,825,985 shares of the stock are valued at $1.33 million. The third largest holder is Nexthera Capital Lp, which currently holds $1.01 million worth of this stock and that ownership represents nearly 2.26% of its market capitalization.OncoSec Medical Incorporated 13F Filings
At the end of September reporting period, 12 institutional holders increased their position in OncoSec Medical Incorporated (NASDAQ:ONCS) by some 82,004 shares, 13 decreased positions by 6,357,697 and 15 held positions by 978,205. That puts total institutional holdings at 7,417,906 shares, according to SEC filings. The stock grabbed 4 new institutional investments totaling 23,663 shares while 6 institutional investors sold out their entire positions totaling 54,485 shares.OncoSec Medical Incorporated (NASDAQ:ONCS) Insider Trades
Multiple company employees have indulged in significant insider trading. OncoSec Medical Incorporated disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Demesa James M has acquired 8,500 shares of OncoSec Medical Incorporated (ONCS) in trading session dated Nov. 20, 2018. These shares are worth $6,970 and were traded at $0.82 each. The SEC filing shows that O’Connor Daniel J. performed a purchase of 10,000 shares. The CEO & President added these shares by way of transaction on Nov. 07, 2018. The company’s shares were assimilated at $0.91 per share worth to an investment of some $9,100 on account of O’Connor Daniel J..
Director, Dhillon Punit, sold 220,440 common shares of OncoSec Medical Incorporated (ONCS) in the open market. In a transaction dated Jul. 05, 2018, the shares were put up for sale at an average price of $1.38, raking in a sum of $304,207. After this sale, 485,262 common shares of ONCS are directly owned by the insider, with total stake valued at $354,241.
In the transaction dated Jul. 05, 2018, the great number of shares disposed came courtesy the Director; Dhillon Avtar S disposed a total of 37,575 shares at an average price of $1.39, amounting to approximately $52,229. The insider now directly owns 143,427 shares worth $104,702.OncoSec Medical Incorporated (ONCS) Analyst Guide
Several analysts have released their opinion on OncoSec Medical Incorporated (NASDAQ:ONCS), with 0 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.33 average brokerage recommendation.